$0.46
1.67% yesterday
Nasdaq, Jun 30, 10:00 pm CET
ISIN
US00444T1007
Symbol
TLPH
Sector
Industry

AcelRx Pharmaceuticals, Inc. Stock price

$0.46
-0.03 6.27% 1M
-0.07 14.00% 6M
-0.06 12.19% YTD
-0.46 49.78% 1Y
-4.43 90.58% 3Y
-23.74 98.10% 5Y
-84.34 99.46% 10Y
-90.54 99.49% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
-0.01 1.67%
ISIN
US00444T1007
Symbol
TLPH
Sector
Industry

Key metrics

Basic
Market capitalization
$9.6m
Enterprise Value
$4.2m
Net debt
positive
Cash
$5.4m
Shares outstanding
17.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
319.85 | 348.58
EV/Sales
140.19 | 152.87
EV/FCF
negative
P/B
1.43
Financial Health
Equity Ratio
43.87%
Return on Equity
-162.53%
ROCE
-107.08%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$30.0k | $27.5k
EBITDA
- | -
EBIT
$-13.9m
Net Income
$-11.6m | $-7.0m
Free Cash Flow
$-13.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-
Net Income
- | 46.31%
Free Cash Flow
12.29%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-51,596.30%
Net
-43,122.22% | -25,333.33%
Free Cash Flow
-49,148.15%
More
EPS
$-0.45
FCF per Share
$-0.78
Short interest
1.06%
Employees
13.00
Rev per Employee
$0.00
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.03 0.03
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.50 7.50
-
25,000%
- Research and Development Expense 6.45 6.45
-
21,500%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
-
-46,437%
Net Profit -12 -12
-
-38,800%

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AcelRx Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 2 months ago
Talphera, Inc. (NASDAQ:TLPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil Aslam - Chief Medical Officer Conference Call Participants Operator Welcome to the Talphera First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page ...
Neutral
PRNewsWire
about 2 months ago
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at...
Neutral
PRNewsWire
about 2 months ago
SAN MATEO, Calif. , May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conf...
More AcelRx Pharmaceuticals, Inc. News

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 13
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today